Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRE-HF: Prognostic Usefulness of I-123 mIBG in Heart Failure
NCT00126425Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Jul 2005
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iobenguane in heart failure (HF), sponsored by GE HealthCare. Primary endpoint: Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio at 24 months. Started Jul 2005; status: completed.
02
Drugs
Iobenguane
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00126425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126425.